This MedLibrary.org supplementary page on Isocarboxazid is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Isocarboxazid
|
|
| Systematic (IUPAC) name | |
| N'-benzyl-5-methyl-oxazole-3-carbohydrazide | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H13N3O2 |
| Mol. mass | 231.26 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Liver |
| Half life | ? |
| Excretion | Urine |
| Therapeutic considerations | |
| Pregnancy cat. |
C (USA) |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Isocarboxazid is a nonselective hydrazine-derived monoamine oxidase inhibitor used in treatment resistant depression.
Contents |
Uses
Approved
In the United States, isocarboxazid is approved for the treatment of depression, anxiety (panic disorder) with or without agoraphobia.
In the United Kingdom, isocarboxazid is licensed for the treatment of depression unresponsive to selective serotonin reuptake inhibitors (SSRIs).
Off-Label/Unapproved/Investigational
A randomized controlled trial published in December 1988 found that isocarboxazid significantly reduced bingeing and purging in bulimia nervosa, regardless of the presence or absence of depression or personality disorder.
Brand Names
United States
MARPLAN by Hoffmann-La Roche, starting in 1959 and discontinuing in 1994. After much patient and physician outcry, they resumed manufacturing just enough Marplan to distribute on an as-needed basis. In October of 1998, Hoffmann-La Roche and Oxford Pharmaceutical Services Inc. announced that Oxford, "is acquiring ownership of the NDA for the antidepressant product Marplan (isocarboxazid) from Roche."
The maximum daily dose of isocarboxazid is 60mg.
United Kingdom
Isocarboxazid is availably generically in the United Kingdom in the form of 10mg tablets. However, it is considered 'less suitable for prescribing' by the British National Formulary (BNF).
References
- drugs.com Isocarboxazid Drug Information
- Monoamine-oxidase inhibitors (Group PIM G025) IPCS INTOX Databank
- PubChem Substance Summary: Isocarboxazid National Center for Biotechnology Information.
- ^ Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE. "A trial of isocarboxazid in the treatment of bulimia nervosa." Journal of Clinical Psychopharmacology. 1988 Dec;8(6):391-6. PMID 3069879
- ^ Marplan Press Release Oxford Pharmaceutical Services.
|
|||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 29 August 2008, at 16:24.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Isocarboxazid".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.